Carl Ross has more than 26 years of experience advancing a wide range of cell and gene therapies, vaccines and therapeutic proteins into human clinical trials.
As you bite into your next peanut butter and jelly sandwich, chew on this: The peanut you’re eating has a secret.
Ophelia Venturelli's research may lead to the ability to engineer behaviors among beneficial microbes in the gut ecosystem, which could be used to enhance their resilience to invasion by pathogens or unintended impairment from antibiotics.
A method that emerged from a UW–Madison spinoff company is in clinical trials in Europe, Asia and the United States against the infection, which can destroy the liver.
Mitochondrial diseases strike about 1 in 4,000 people and there are currently no licensed therapies available beyond treatments with vitamins and supplements.
With a unique approach that draws on 3-D printing technologies, a team of UW–Madison researchers is developing new tools for understanding how ovarian cancer develops in women.
The findings provide the foundation for future antiviral drug and vaccine development against rhinovirus C.
The company makes cutting-edge products based on discoveries by three UW scientists for delivering DNA and RNA into cells.